6 Green Days In A Row: AbCellera Biologics Stock Is Up 85%
A biotech stock’s sudden surge puts its fundamentals in the spotlight, revealing a mix of rapid growth and deep losses.
AbCellera Biologics (ABCL) stock has now moved higher for 6 consecutive trading days, delivering a cumulative gain of 85% over the period. That streak has added about $1.5 billion to the company’s market value, which now stands at about $3.4 billion.
For anyone holding the stock, this run has pushed its price to a new 52-week high of $10.97. The move builds on recent strength, with the stock having returned +130.0% over the trailing three months and +156.9% over the trailing twelve months.
ABCL Versus The S&P 500, Streak And Beyond
Here is how ABCL stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | ABCL | S&P 500 |
|---|---|---|
| 1D | 5.9% | 0.7% |
| 6D (Current Streak) | 85.3% | 1.0% |
| 1M (21D) | 62.8% | 3.0% |
| 3M (63D) | 130.0% | 4.8% |
| YTD 2026 | 220.8% | 13.9% |
| 2025 | 16.7% | 16.4% |
| 2024 | -48.7% | 23.3% |
| 2023 | -43.6% | 24.2% |
What do the fundamentals say about this run?
The data presents a mixed picture. On one hand, revenue over the last twelve months grew 101.3%, far outpacing the S&P 500 median revenue growth of 8.3%. However, the company’s 3-year average annual revenue growth is a more moderate 7.8%.
On the other hand, profitability is a challenge. The operating margin over the last twelve months is -318.7%, compared to an S&P 500 median of 18.4%. ABCL also has negative trailing earnings. The stock’s move is its own story, as the S&P 500 returned just +1.0% over the same 6 trading days. For context, 7 S&P 500 stocks are currently on winning streaks of 6 days or more.
So how should I think about a streak like this?
A streak is a piece of information, not an instruction. It tells you that a stock has captured the market’s attention and has strong short-term momentum. It does not, by itself, tell you whether the stock is a good or bad investment at the new price.
The disciplined response is to use the streak as a prompt to check your thesis. The market has repriced the company higher. The task is to weigh the evidence, like the rapid recent revenue growth against the significant operating losses, and decide if the business fundamentals still support the stock’s new valuation.
If you are hunting for strength that has more behind it than a hot tape, our Guidance Momentum screen surfaces the names where management raised its own outlook, which is the kind of momentum that tends to persist.
And for anyone who would rather back the theme than one company’s story, our ETF Scorecard shows how the biotech funds stack up. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Streaks End. Discipline Compounds
A run like this is genuinely useful information: something about this business has the market’s full attention. But streaks are where discipline gets tested, because the urge to chase strength is strongest right before it pauses.
The Trefis High Quality (HQ) Portfolio channels that urge into a system: roughly 30 businesses selected for consistent cash generation, strong margins, and resilient balance sheets, sized and rebalanced with rules rather than excitement. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Enjoy the streak; own the process.